Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05948826
Other study ID # TORL3600-001
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date September 29, 2023
Est. completion date September 15, 2026

Study information

Verified date March 2024
Source TORL Biotherapeutics, LLC
Contact Stephen Letrent, PharmD, PhD
Phone 858-342-6652
Email stephen.letrent@torlbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date September 15, 2026
Est. primary completion date September 15, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Advanced solid tumor - Measurable disease, per RECIST v1.1 - Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - Adequate organ function Exclusion Criteria: - Has not recovered [recovery is defined as NCI CTCAE, version 5.0, grade =1] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements - Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-3-600 - Progressive or symptomatic brain metastases - Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection - History of significant cardiac disease - History of myelodysplastic syndrome (MDS) or AML - History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. A history of other malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate cancer with a Gleason score less than or equal to 6, are also not excluded - If female, is pregnant or breastfeeding

Study Design


Intervention

Drug:
TORL-3-600
antibody drug conjugate

Locations

Country Name City State
Canada McGill University Health Centre Montréal Quebec
Canada University Health Network, Princess Margaret Cancer Centre Toronto Ontario
United States Mary Crowley Cancer Research Dallas Texas
United States UCLA - JCCC Clinical Research Unit Los Angeles California
United States Washington University School of Medicine-Siteman Cancer Center Saint Louis Missouri

Sponsors (2)

Lead Sponsor Collaborator
TORL Biotherapeutics, LLC Translational Research in Oncology

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and severity of adverse events and serious adverse events Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0 up to 2 years
Primary Maximum Tolerated Dose (MTD) Highest administered dose with < 33% participants experiencing dose limiting toxicity (DLT) in the first 6 DLT evaluable participants 28 Days
Primary Recommended Phase 2 Dose (RP2D) Based on the maximum tolerated dose, cumulative safety, and pharmacokinetic data up to 2 years
Secondary Objective Response Rate (ORR) Percentage of participants with best response of complete response (CR) or partial response (PR) according to RECIST 1.1 up to 2 years
Secondary Duration of Response (DOR) Time from CR or PR to objective disease progression or death to any cause up to 2 years
Secondary Progression Free Survival (PFS) PFS is defined as the time from the start of the treatment until objective disease progression or death from any cause up to 2 years
Secondary Time to Response (TTR) Time from start of treatment to complete response or partial response up to 2 years
Secondary 1 Year Overall Survival (1YOS) Proportion of participants alive at 1 year from the start of treatment to death from any cause 1 year
Secondary 2 Year Overall Survival (2YOS) Proportion of participants alive at 2 years from the start of treatment to death from any cause 2 years
Secondary Number of anti-drug antibody (ADA) Positive Participants Immunogenicity will be measured by the number of participants that are ADA positive. up to 2 years
Secondary Maximum Serum Concentration of TORL-3-600 (Cmax) PK assessment 21 days
Secondary Minimum Serum Concentration of TORL-3-600 (Cmin) PK assessment 21 days
Secondary Maximum Serum Concentration of TORL-3-600 at Steady State (Cmax,ss) PK assessment 63 days
Secondary Minimum Serum Concentration of TORL-3-600 at Steady State (Cmin,ss) PK assessment 63 days
Secondary Time of Maximum Serum Concentration of TORL-3-600 (Tmax) PK assessment 21 days
Secondary Time of Minimum Serum Concentration of TORL-3-600 (Tmin) PK Assessment 21 days
Secondary Time of Minimum Serum Concentration of TORL-3-600 at Steady State (Tmin,ss) PK Assessment 63 days
Secondary Terminal Half-life (t1/2) of Serum TORL-3-600-ADC PK Assessment 63 days
Secondary Area under the Serum Concentration-Time curve from the time of dosing to the last measurable concentration (AUClast) for TORL-1-23 PK Assessment 21 days
Secondary Area under the Serum Concentration-Time curve from the time of dosing extrapolated to time infinity (AUCinf) for TORL-1-23 PK Assessment 63 days
Secondary Apparent volume of distribution during the terminal phase (Vz) of TORL-3-600 PK Assessment 63 days
Secondary Clearance (CL) of TORL-3-600 PK Assessment 63 days
Secondary Accumulation ratio (Rac) of TORL-3-600 PK Assessment 63 days
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A